Accustem Sciences Inc.

Accustem Sciences Inc. is a clinical-stage diagnostics company focused on developing genomic tests for oncology decision-making. Its core programs are MSC (MicroRNA Signature Classifier) for patients with lung nodules and StemPrintER for early-stage breast cancer, with plans to expand the StemPrint platform into additional tumor types. The company is still in the development and commercialization-build phase and has not yet generated product revenue. It is working through laboratory transfer, CLIA certification, and reimbursement milestones before launching its tests commercially in the United States.

0.01

0.01

— Accustem Sciences Inc.
%
Oncology genomic classifiers70% Proprietary molecular tests intended to support cancer diagnosis and treatment decisions, including MSC and StemPrintER.
Ancillary laboratory testing30% Commodity tests offered alongside the core classifiers to improve customer value and laboratory utilization.

Accustem’s customers are expected to be clinicians and healthcare systems that need genomic information to guide...

  • Lung nodule care providersprimary

    Clinicians and institutions evaluating lung nodules who would use MSC to support diagnosis and management decisions.

  • Early-stage breast cancer providersprimary

    Oncology providers treating early-stage breast cancer who would use StemPrintER to inform care decisions.

  • Ancillary test buyerssecondary

    Customers purchasing add-on molecular tests such as next-generation sequencing, IHC receptor status, and hereditary panels.

  • Partner laboratory channelsecondary

    Commercial laboratory partners that process, test, and report results for commercial samples.

Accustem is headquartered and operates from New York, NY and London, UK, while substantially all of its assets are...

  • •Headquarters and operations in New York, NY and London, UK
  • •Substantially all assets located in the United States
  • •Initial commercialization targeted at the U.S. market
  • •Commercial lab partner located in Lake Forest, California
  • •Potential future expansion into other markets after U.S. launch

Accustem’s strategy is to move from clinical development into commercial launch by completing the operational...

01
Commercialize MSC in the U.S.short-term

MSC needs clinical validation, laboratory transfer, and reimbursement readiness before it can generate revenue.

02
Build reimbursement supportshort-term

Peer-reviewed publications and payer acceptance are required for adoption and monetization of the genomic classifier.

03
Expand the StemPrint platformmedium-term

Broader tumor-type coverage could increase the commercial opportunity beyond breast cancer.

The company faces execution risk because it has no approved commercial products and must complete several technical and...

critical

Going-concern and financing dependence

The company has no revenue, no committed external funding, and ongoing losses.

Scope
Liquidity and operating continuity
Materiality
high
high

Commercialization milestone delays

MSC and StemPrintER require lab transfer, validation, and CLIA certification before clinical launch.

Scope
Launch timing and first revenue generation
Materiality
high
high

Reimbursement uncertainty

The company states that peer-reviewed publications and payer reimbursement are necessary for commercialization.

Scope
Adoption and pricing
Materiality
high
high

Internal control weakness

Management disclosed ineffective controls due to lack of accounting resources and inadequate segregation of duties.

Scope
Financial reporting reliability
Materiality
medium
Material weakness in internal controls
Raises the risk of financial statement error and delayed reporting
R&D expense volatility
Makes operating loss trends less comparable across periods
Pre-revenue accounting
Financial statements are dominated by expense recognition and financing activity

Cogent Biosciences, Inc.

COGT · Pharmaceutical Preparations

ACHIEVE LIFE SCIENCES, INC.

ACHV · In Vitro & In Vivo Diagnostic Substances

EXACT SCIENCES CORP

EXAS · Services-Medical Laboratories

PRECISION BIOSCIENCES INC

DTIL · Biological Products, (No Diagnostic Substances)

NextCure, Inc.

NXTC · Pharmaceutical Preparations

Advanced Biomed Inc.

ADVB · Services-Medical Laboratories

: 11/08/2026